CUV
CLINUVEL PHARMACEUT. ORDINARYClinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
CUV
CUV
CLINUVEL PHARMACEUT. ORDINARY
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
Fundamentals
Historical Data63 days
| Date | Short % | Gross Short |
|---|---|---|
| 16 July | — | — |
| 15 July | — | — |
| 14 July | — | — |
| 13 July | 8.92% | — |
| 10 July | 8.88% | — |
| 9 July | 8.95% | — |
| 8 July | 9.00% | — |
| 7 July | 9.10% | — |
| 6 July | 9.15% | — |
| 3 July | 9.19% | — |
| 2 July | 9.24% | — |
| 1 July | 9.25% | — |
Clinuvel Pharmaceut (CUV) Short Interest Summary
Clinuvel Pharmaceut (CUV) currently has 8.92% of its shares sold short (4.5 million shares, worth approximately $45.5 million), based on ASIC short position data reported on 13 July 2026 (T+4 reporting lag). That makes CUV the #23 most shorted stock on the ASX most shorted list. Short interest in CUV is down 0.23% over the past week and down 0.45% over the past month. CUV is part of the Health Care sector on the ASX.
Recent CUV Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 13 July 2026 | 8.92% | 4.5M | $10.22 |
| 10 July 2026 | 8.88% | 4.5M | $10.27 |
| 9 July 2026 | 8.95% | 4.5M | $10.45 |
| 8 July 2026 | 9.00% | 4.5M | $10.28 |
| 7 July 2026 | 9.10% | 4.6M | $10.29 |
| 6 July 2026 | 9.15% | 4.6M | $10.21 |
| 3 July 2026 | 9.19% | 4.6M | $10.25 |
| 2 July 2026 | 9.24% | 4.7M | $10.26 |
| 1 July 2026 | 9.25% | 4.7M | $10.42 |
| 30 June 2026 | 9.28% | 4.7M | $10.28 |
CUV Short Selling — Frequently Asked Questions
What is Clinuvel Pharmaceut (CUV)'s current short interest?
Clinuvel Pharmaceut (CUV) currently has a short interest of 8.92% of total shares outstanding. This means 8.92% of CUV's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is CUV heavily shorted on the ASX?
CUV has a moderate level of short interest at 8.92%. While below the heavily shorted threshold of 10%, this indicates notable bearish positioning. CUV is currently ranked #23 among the most shorted stocks on the ASX.
What does short interest mean for CUV investors?
Short interest in CUV shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 8.92%, CUV's short interest is at a moderate level. See our short squeeze candidates and days to cover analysis for more context.
Where does this CUV short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for CUV.